13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC

This statement is filed by:

(i)

Matrix Capital Management Company LP (the “Investment Manager”),
a Delaware limited partnership, and the investment adviser to Matrix Capital Management Master Fund, LP (the “Matrix Fund”),
with respect to the Shares (as defined in Item 2(d) below) represented by the ADSs directly held by the Matrix Fund; and

(ii)

Mr. David E. Goel (the “Mr. Goel“), the Managing General Partner of the Investment Manager, with respect to the Shares represented by the ADSs directly held by the Matrix Fund.

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC – ADR (ADAP)

Published on September 12, 2017 at 11:42 am by Insider Monkey Staff in Hedge Funds

Page 4 of 8 – SEC Filing

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on April 11, 2024 at by Inan Dogan, PhD

50-year Wall Street Insider Names #1 stock for AI “Tidal Wave”

Published on April 1, 2024 at by Insider Monkey Staff

Item 1(a).	NAME OF ISSUER.

	The name of the issuer is Adaptimmune Therapeutics PLC (the “Company“).

Item 1(b).	ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

	The Company’s principal executive offices are located at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom.

Item 2(d).	TITLE OF CLASS OF SECURITIES:

	Ordinary Shares, par value £0.001 (the “Shares“).